Additional small molecular strategies include phosphatidylinositol-3-kinase (PI3K) inhibitors like idelalisib, which inhibit critical PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathways for CLL cell survival [107,108]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.